Indeed, in vitro and ex vivo studies demonstrated the capacity of pomalidomide to reduce Ikaros and Aiolos levels in ILCs and, more interestingly, to enhance IFN-γ production by ILC1 from both healthy controls and MM patients. The gene discussed is IFNG; the disease is Miyoshi myopathy.